½Ã°£ |
¹øÈ£ |
¼º¸í |
¼Ò¼Ó |
Á¦¸ñ |
ÁÂÀå : ±è¿µÅÂ(¿¬¼¼ÀÇ´ë) |
13:00~13:40 |
GO1 |
Á¤¿ë¿í |
¿¬¼¼ÀÇ´ë |
Robot-assisted staging using three robotic arms for endometrial cancer: Comparison to laparoscopy and laparotomy at a single institution |
GO2 |
½Å¼ÒÁø |
°è¸íÀÇ´ë |
Regulatory Role of Osteopontin in Malignant Transformation of Endometrial Cancer |
GO3 |
µ¿¼¿¬ |
°æÈñÀÇ´ë |
Association of the hSRBC gene polymorphism with endometrial cancer |
GO4 |
Á¤±Ù¿À |
°æºÏÀÇ´ë |
Role of FDG PET in detecting myometrial invasion in patients with clinical stage I endometrial cancer |
ÁÂÀå : ¹è´ö¼ö(¼º±Õ°üÀÇ´ë) |
13:40~14:20 |
GO5 |
³²ÁÖÇö |
¿ï»êÀÇ´ë |
The integration of aggressive surgical procedures to achieve optimal cytoreduction improves the survival of patients with FIGO stage IIIC-IV epithelial ovarian cancer |
GO6 |
¹éÁöÈì |
¿¬¼¼ÀÇ´ë |
Utility of HE4 and CA125 as multiple serum tumor markers for the prediction of ovarian cancer |
GO7 |
Á¶ÇѺ° |
¿¬¼¼ÀÇ´ë |
Gene and protein expression profiling of newly established ovarian cancer cell lines: Identification of TOM40 and NP for ovarian cancer diagnosis and therapy |
GO8 |
ÀÌÈñÁØ |
¼¿ïÀÇ´ë |
Oxaliplatin, Leucovorin and 5-fluorouracil (FOLFOX-4) in Refractory Epithelial Ovarian Cancer: A Single Institutional Experience, 2002-2009 |
ÁÂÀå : ±è½Âö(ÀÌÈÀÇ´ë) |
14:20~15:00 |
GO9 |
À̽ÅÈ |
¿ï»êÀÇ´ë |
Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix; a retrospective matched case-control study |
GO10 |
À¯½Âö |
¾ÆÁÖÀÇ´ë |
A validation study of new risk grouping criteria for tailoring postoperative adjuvant treatment in stage IB cervical cancer patients without high-risk factors: Rethinking the use of the GOG criteria |
GO11 |
±èÀ±È¯ |
¼¿ïÀÇ´ë |
Prognostic Significance of VEGF Polymorphisms in Early Cervical Cancer |
GO12 |
À̼öÀ± |
ÀÌÈÀÇ´ë |
Genetic polymorphism of ataxia telangiectasia mutated and cervical neoplasia risk in Korean women. |
ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë) |
15:00~15:40 |
GO13 |
Àü¿µÀº |
¿¬¼¼ÀÇ´ë |
Identification of STIP-1 as a Diagnostic and Therapeutic Biomarker Candidate for Ovarian Cancer by two-dimensional DITA (differential gel electrophoresis analysis of immunoprecipitated tumor antigens) |
GO14 |
±è±âÇü |
ºÎ»êÀÇ´ë |
The Antitumor activity and Molecular mechanism of novel isoflavone derivative NV-128 in Epithelial ovarian cancer cells |
GO15 |
Á¶µ¿ÈÞ |
ÀüºÏÀÇ´ë |
Awareness of human papillomavirus among public health officials |
GO16 |
Á¶Á¤¾Æ |
¼º±Õ°üÀÇ´ë |
Tumor-derived exosomes can induce differentiation of mesenchymal stem cells into tumor-associated myofibroblastic cells |
ÁÂÀå : ÃÖÈ£¼±(Àü³²ÀÇ´ë) |
15:40~16:20 |
GO17 |
ÀÌÈ«ÁÖ |
ÇѾçÀÇ´ë |
Comparison of Mathematical Models to Detect Malignant pelvic masses in the preoperative evaluation |
GO18 |
À̼ºÇÏ |
°¡Å縯ÀÇ´ë |
A clinicopathologic study in 1,042 patients with invasive cervical cancer: 10 years experience at the Department of Obstetrics and Gynecology of Kangnam St. Mary¡¯s hospital |
GO19 |
À±¼®±Ù |
°üµ¿ÀÇ´ë |
Evaluation of prognostic factors and clinical outcomes in uterine sarcoma |
GO20 |
¼ÛÀçÀ± |
°í·ÁÀÇ´ë |
Body Mass Index change during Chemotherapy and prognosis in advanced ovarian cancer |
ÁÂÀå : ³ëÈïÅÂ(Ãæ³²ÀÇ´ë) |
16:20~17:00 |
GO21 |
ÀÌÀ¯¹Ì |
Â÷ÀÇ´ë |
Comparison of results of treatment of patients with GTN referred to a trophoblastic disease center after failure of treatment elsewhere and primarily treated at trophoblastic disease center |
GO22 |
¿À¹ÎÁ¤ |
Àü³²ÀÇ´ë |
Significance of Human Papillomavirus Genotyping with High-grade Cervical Intraepithelial Neoplasia Treated by a Loop Electrosurgical Excision Procedure |
GO23 |
±è±âµ¿ |
¿øÀڷº´¿ø |
Risk factors for central failure in patients with locally advanced cervical cancer |
GO24 |
¼ÛÀº¼· |
ÀÎÇÏÀÇ´ë |
Clinical Analysis of Patients with of LSIL |